EUVIMEDEUVIMED entdecken
Metaanalyse

Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials

Joseph J Zhao, Kennedy Yao Yi Ng, Raghav Sundar, Samuel J Klempner

Cancer Treatment Reviews · 2025-11 · 140 · 103002

DOI: 10.1016/j.ctrv.2025.103002 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Cancer Treatment Reviews, 2025-11. Verfasst von Joseph J Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, National University Hospital, Singapore, Singapore; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore;…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Immune Checkpoint Inhibitors, Stomach Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: National University of Singapore, National Institutes of Health, SingHealth.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsImmune Checkpoint InhibitorsStomach NeoplasmsHumansClinical Trials, Phase III as TopicPerioperative CareRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Gastroesophageal cancerImmune checkpoint inhibitionPerioperative

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, National University Hospital, Singapore, Singapore; Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Si…
  • Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; Oncology Academic Program, Duke-NUS Medical School, Singapore, Singapore.
  • Department of Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, CT, USA.
  • Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, MA, USA. Electronic address: sklempner@mgb.org.

Förderung

  • National University of Singapore
  • National Institutes of Health
  • SingHealth
  • Dana-Farber/Harvard Cancer Center
  • Government of Singapore Ministry of Health
  • National Medical Research Council
  • Dana Foundation
  • National University Health System

Zitieren

APA

Zhao, J. J., Yi Ng, K. Y., Sundar, R., & Klempner, S. J. (2025). Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials. Cancer Treatment Reviews, 140, 103002. https://doi.org/10.1016/j.ctrv.2025.103002

Vancouver

Zhao JJ, Yi Ng KY, Sundar R, Klempner SJ. Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials. Cancer Treatment Reviews. 2025;140:103002. doi:10.1016/j.ctrv.2025.103002

BibTeX
@article{Zhao2025,
  author = {Zhao, Joseph J and Yi Ng, Kennedy Yao and Sundar, Raghav and Klempner, Samuel J},
  title = {Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  volume = {140},
  pages = {103002},
  doi = {10.1016/j.ctrv.2025.103002}
}
Kostenlos starten →